Research: Asian Regulatory Bodies (SAMR and FSSAI)
Summary
This source provides a detailed analysis of the regulatory landscape for beverages in Asia’s two largest consumer markets: China and India. It outlines the specific frameworks governed by the state-administration-for-market-regulation-samr (SAMR) in China and the food-safety-and-standards-authority-of-india-fssai (FSSAI) in India. The research highlights the complexities global beverage conglomerates like asahi-group-holdings face regarding abv-threshold-divergence, functional-beverage-regulations, and the lack of international ingredient reciprocity.
Key Findings
China’s Tripartite Regulatory System
Beverage regulation in China is divided among three primary agencies:
- state-administration-for-market-regulation-samr (SAMR): Oversees domestic market supervision and quality inspections.
- national-health-commission-nhc (NHC): Drafts national food safety standards and manages the registration of new food ingredients, functioning similarly to the EU’s novel-food-regulations.
- general-administration-of-customs-of-china-gacc (GACC): Handles customs clearance and the mandatory registration of overseas food and beverage manufacturers. Additionally, new digital labeling requirements (GB 7718-2025) will take effect in March 2027, requiring brands to adapt their packaging architecture.
India’s FSSAI and ABV Thresholds
The food-safety-and-standards-authority-of-india-fssai enforces a strict four-tier classification system that exemplifies abv-threshold-divergence:
- Alcoholic Beverages: >0.5% ABV.
- Low Alcoholic Beverages / RTD: >0.5% to 8.0% ABV.
- Non-Alcoholic Counterparts: ⇐0.5% ABV.
- Alcohol-Free Beer: Strictly 0.0% ABV.
A critical 2020 amendment by FSSAI explicitly defined “alcohol-free beer” as 0.0%, resolving severe administrative ambiguity that previously caused import delays for products like Asahi Super Dry 0.0%.
Functional Beverage Challenges
As the market shifts toward functional premiumization using adaptogens and nootropics, brands face significant legal friction. Asian regulators heavily scrutinize the line between permissible structure-function-vs-drug-claims and illegal medical claims. Crucially, there is a lack of international ingredient reciprocity: an ingredient holding GRAS status with the US FDA is not automatically permitted by China’s NHC or India’s FSSAI, often requiring separate, exhaustive pre-market approvals.